Showing papers in "European Journal of Cancer in 2011"

TL;DR: Clinical evidence shows that filgrastim, lenograstim and pegfilgrastIM have clinical efficacy and the use of any of these agents to prevent FN and FN-related complications where indicated and prophylactic G-CSF support is recommended.

TL;DR: The results of the present study show that systemic inflammation-based scores, in particular the mGPS and PI, have prognostic value in cancer independent of tumour site.

TL;DR: Estimates of the rare cancer burden in Europe provide the first indication of the size of the public health problem due to these diseases and constitute a useful base for further research.

TL;DR: Findings from this meta-analysis strongly support that diabetes is associated with an increased risk of PaC in both males and females and that DM is both an early manifestation and an etiologic factor of pancreatic cancer.

TL;DR: Irinotecan as second-line chemotherapy significantly prolongs overall survival compared to BSC in the studied pts and can now be considered as a proven treatment option for metastatic or locally advanced gastric cancer.

TL;DR: This trial, conducted prior to the reporting of registrational phase III trials, found that sorafenib did not significantly prolong TTP in patients who responded to TACE.

TL;DR: This study identified a serum microRNA expression profile that can serve as a novel diagnostic biomarker for GC detection and assess its clinical applications in monitoring disease progression.

TL;DR: Meta-analysis in patients with localised high-grade osteosarcoma shows that 3-drug regimens, for example MAP are the most efficacious drug regimens and Salvage of poor responders by changing drugs, or intensifying treatment postoperatively has not proven to be useful.

TL;DR: This paper describes the rationale and design of PROFILES, a registry for the study of the physical and psychosocial impact of cancer and its treatment from a dynamic, growing population-based cohort of both short and long-term cancer survivors.

TL;DR: Although stopped prematurely, this randomized trial provides at first time evidence for the benefit of second-line chemotherapy as compared to BSC alone for patients with APC.

TL;DR: Despite no difference in survival, the improvement from preoperative CRT with respect to margin involvement makes this treatment a reasonable option for bulky, locally advanced resectable adenocarcinoma of the oesophagus.

TL;DR: Addition of MRI to routine clinical care in patients with nonpalpable breast cancer was paradoxically associated with an increased re-excision rate, and breast MRI should not be used routinely for preoperative work-up of patients withNonpalpables breast cancer.

TL;DR: The current knowledge in this area is reviewed, including evidence of miRNA involvement in cancer drug resistance, and many pro-apoptotic miRNAs target anti-APoptotic mRNAs or their positive regulators.

TL;DR: Insight is provided into recent findings on the molecular mechanisms of leptin and adiponectin in mammary tumours, and the potential interplay between these two adipokines in breast cancer is discussed.

TL;DR: This study confirms that pregnancy in women with history of breast cancer is safe and does not compromise their overall survival, and breast cancer survivors should not be denied the opportunity of future conception.

TL;DR: It is confirmed that pathologic response is a prognostic indicator for RFS, DFS and OS and suggests that patients achieving pCR after NAC have favourable outcomes.

TL;DR: It seems that the dysregulation of miRNAs involved in apoptosis may provide a mechanism for cancer development, and manipulating miRNA expression level may be a potential therapeutic strategy for curing cancer.

TL;DR: Extended schedule escalated dose temozolomide (7 days on 7 days off) is feasible and has an acceptable safety profile, but does not improve OS and PFS in metastatic melanoma when compared to standard dose dacarbazine.

TL;DR: GPC3 is a promising candidate for liver cancer therapy given that it shows high expression in HCC and there is also evidence that soluble GPC3 may be a useful serum biomarker for HCC.

TL;DR: The results support the current practice of adding concurrent cisplatin plus adjuvant cisPlatin-fluorouracil to radiotherapy for treating patients with locoregionally advanced NPC.

TL;DR: In 2011, a number of new drugs will be approved for melanoma, including immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand CTLA-4.

TL;DR: Dutch men and women reported high levels of overall QoL as compared to previously published Scandinavian and German normative data, and men scored statistically but never clinically significantly better on most functional scales than women.

TL;DR: This study shows that including ultrasound as adjunct screening in women with D3-D4 breasts brings the IC rate to similar levels as IC in non-dense breasts, which suggests that additional cancer detection by ultrasound is likely to improve screening benefit in dense breasts, and supports the implementation of a randomised trial of adjunct ultrasound in Women with increased breast tissue density.

TL;DR: This is the first randomized study on the efficacy of RFA and the study met the primary end point on 30-month OS; however, the results in the control arm were in the same range.

TL;DR: Final overall survival analysis of the GBG-26 study did not demonstrate a significant survival benefit for treatment beyond progression with trastuzumab, however, in a post-hoc analysis, patients receiving anti-HER2 treatment as 3rd line therapy showed a better post-progression survival than those not receiving this targeted treatment.

TL;DR: A negative HPV test was significantly more protective than normal cytology over three rounds, suggesting that the screening interval could be extended to 6 years if HPV testing replaced cytology as the primary screening test.

TL;DR: The successful application of intra-lymphatic delivery of chemotherapeutic drugs using mMWNTs highlights the clinical potential of fCNTs for future cancer metastasis treatment with high efficacy and minimum side-effects.

TL;DR: This meta-analysis suggests that excess body weight is a risk factor for multiple myeloma, and is in line with the conclusions of the previous meta-analyses.

TL;DR: Some of the herbs with promising case report findings have undergone prospective clinical investigations but many others have either not yet been explored or the results have not been reported in English.

TL;DR: The results suggest that down-regulation of Drosha and/or Dicer is not robustly associated with the outcome of breast cancer patients treated with adjuvant anthracycline-based chemotherapy but preferentially observed in distinct subgroups of breast cancers.